drugs Flashcards
Gemtuzumab
anti-CD33 linked to ozogamicin atb
blinatumomab (including toxicities)
BITE - CD3 and CD19, brings T cell to tumor cells
toxicities: myelosuppression, infusion reaction, headache, nausea, cytokine release syndrome (IL-6)
tocilizumab
anti-IL6
CRS
Inotuzumab
antibody-drug conjugate - CD22 targeted antibody linked to calicheamicin (antibiotic)
HR-ALL
UFH mechanism, monitoring, pro/con, antidote
binds/potentiates antithrombin III activity (IIa > Xa)
PTT q4h until stable dose then daily
short half life (30 min) and reversible
need for continuous inf, risk of HIT, dependent on AT III
protamine sulfate
LMWH mechanism, monitoring, pro/con, antidote
binds/potentiates antithrombin III activity (Xa > IIa)
AntiXa 4h post dose
BID dosing, no access requiring, predictable PK
only partial reveral, dependent on AT III
protamine sulfate (partial)
DOAC mechanism, monitoring, pro/con, antidote
anti-XA inhibition
no monitoring
oral, predictable PK
no reversal, rx interactions, need <120kg
no reveral (andexanet alfa in adults)
Warfarin mechanism, monitoring, pro/con, antidote
Vitamin K antagonist
INR 1/w, target 2-3
oral
++ monitoring, bleeding risk, rx interaction
Vitamin K, PCC/FFP
Fondaparinux and dabigatran mechanisms
Fonda: indirect Xa inhibitor
Dabiga: direct thrombin inhibitor
emicizumab MOA
Bispecific Ab anti-FIX and -X, mimicking action of FVIII
Hemophilia A
DDAVP MOA and contraindications
VWF release from plt stores, protecting FVIII from degradation
Type 3 or 2B VWD
young
HU MOA and toxicities
cytoreduction (decreased infl from neutrophils)
increased HbF
Increased RBC volume/deformability
decreased vascular endothelium adhesion
neutropenia, thrombocytopenia, GI upset, nail/hair, liver, decreased sperm count
Voxelotor
HbS polymerization inhibition, increasing O2 affinity
eltrombopag
thrombopoietin receptor agonist, stimulating megakaryocytic differentiation
alemtuzumab
anti-CD52
depletes T cells: T, B, NK, monocytes; NOT HSC
